Almost the Same, but Not Quite...Biosimilars Market Expected to Hit $25 billion by 2020

SUGAR LAND--March 29, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Generics have long been the bane of Big Pharma. Waiting in the wings until a drug's patent expires, low-cost copycats then flood into the market as pharma companies watch their profits take a dive. The market was once limited to traditional pharmaceutical products, but this is no longer true as a growing number of biopharmaceuticals, or biologics, are headed for their own patent cliff. Within this article: Provides insight on the future of the biosimilars market.